Microsoft Left a Site the Grid Can Power Only in the 2030s. AI Infrastructure Is Duration Risk.
Britain's grid now decides when an artificial intelligence data centre opens, and Ofgem's own model shows that date costs more than its proposed fee, so investors should price compute as long-duration utility risk.
Read More
Base44 Entered 2026 at Near-Zero Gross Margin. AI Targets Need a Cost-to-Serve Diligence Workstream.
Wix's Base44 entered 2026 at near-zero gross margin, and filers book inference on different lines, so buyers must diligence cost to serve per unit before pricing a software target's revenue.
Read More
Beijing Unwound a Closed $2 Billion Deal. Closing Certainty Is Now a Political Variable.
Beijing's order to unwind Meta's closed Manus deal shows closing certainty now depends on the founders' home state, so cross-border sellers must price political reversal into signing.
Read More
Megafunds Took 73% of the Money. The Single-Digit-Billion Exit Is Now an Orphan.
Five firms took 73% of new US venture capital in Q1 2026. Allegory Capital's portfolio model shows why the orphaned single-digit-billion exit rewards investors who diversify across vehicles.
Read More
Users Buy the Product. Organisations Buy the Company.
Product-market fit proves users want the product; procurement fit proves the organisation can buy the company, and in regulated Europe that second fit is an investable asset.
Read More
Big Tech's AI Capex Now Outruns the Cash Flow It Once Minted
The four largest hyperscalers now convert surplus cash into fixed assets faster than those assets earn, making return on capital the variable that decides this trade.
Read More
How Private Credit Is Displacing Bank Debt in Leveraged Buyouts: What It Means for Deal Valuations
<![CDATA[ TLDR: Private credit now funds 77% of leveraged buyouts globally, displacing...
Read More
Why Regulated-Industry Startups Are Capturing Disproportionate Series B Capital in Europe: What the Investment Thesis Actually Requires
TLDR: Regulated-industry startups in healthtech, insurtech, legaltech, and compliance-tech are capturing an...
Read More
ONWARD Medical Skipped Swiss Funds, Found European Specialists, and Reached a Euronext IPO
An investor read: a 'no' from the wrong-mandate fund is information about fit, not a verdict on the company.
Read More
Investors Decide on Founders in the First Ninety Seconds, Not the Pitch Deck
From the other side of the table: what an early-stage investor is actually underwriting is the founder, not the slides.
Read More